Human recombinant tumor necrosis factor (rTNF) was found to act directly on cultured human vascular endothelium to induce a tissue factor-like procoagulant activity (PCA). After a 4-hr incubation in rTNF (100 units/ml), serially passaged endothelial cells isolated from umbilical veins, saphenous veins, iliac arteries, and thoracic aortae demonstrated a dramatic increase (4-to 15-fold, 21 experiments) in total cellular PCA as measured with a one-stage clotting assay. rTNF-induced PCA was also expressed at the surface of intact viable endothelial monolayers. Induction of PCA by rTNF was concentration dependent (maximum, 500 units/ml), time dependent, reversible, and blocked by cycloheximide and actinomycin D, and it occurred without detectable endothelial cell damage. Actions of rTNF were compared with those of natural human interleukin 1 (IL-1) derived from stimulated monocytes and two distinct species of recombinant IL-1, each of which also induced endothelial PCA. The use of recombinant polypeptides and specific neutralizing antisera established the distinct natures of the mediators. The minetics ofthe endothelial PCA responses to TNF and IL-1 werf similar, demonstrating a rapid rise to peak activity at -4 hr, apd a decline toward basal levels by 24 hr. This characteristic decline in PCA after prolonged incubation with TNF or IL-1 was accompanied by selective endothelial hyporesponsiveness to the initially stimulating monokine. Interestingly, the effects of TNF and IL-1 were found to be additive even at apparent maximal doses of the individual monokines. Endothelial-directed actions of TNF, alone or in combination with other monokines, may be important in the initiation ofcoagulation and inflammatory responses in vivo.
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In 1975 Carswell et al. (1) described an activity in the serum of mice primed with bacillus Calmette-Guerin and treated with endotoxin that caused "hemorrhagic necrosis" of certain tumors. This activity was termed "tumor necrosis factor" (TNF) and has begome the subject of extensive research (2) , leading to its ideptification as a monokine, purification and biochemical characterization (2) (3) (4) (5) (6) (7) , and the cloning and expression of its gene (8) (9) (10) (11) . Although initially it was thought that TNF acted only on tumor cells, it has become clear that certain nontumor cells possess TNF receptors (12) (13) (14) and may be targets for other biological activities of this monokine. In separate investigations, Cerami and coworkers described a product of endotoxinstimulated murine macrophages, termed "cachectin," which suppresses the synthesis of lipoprotein lipase by adipocytes (15) (16) (17) . Recently, it has been established that cachectin and TNF appear to be identical (18, 19) and that a specific antiserum to cachectin/TNF can protect mice from the lethal effects of endotoxin (20) .
We now report that human recombinant TNF (rTNF) is a potent inducer of procoagulant activity (PCA) in human endothelial cells cultured from various blood vessels. We compare the effects of rTNF with those of human monocytederived interleukin 1 (hmIL-1) and two distinct species of recombinant human interleukin 1 (rIL-1). We have previously shown that hmIL-1 acts on human endothelial cells to induce a tissue factor-like PCA (21) (22) (23) , to dramatically increase the adhesiveness oftheir surfaces for leukocytes (23, 24) , and to stimulate the expression of a new endothelial surface antigen (25 (50-100 ,ug/ml, Sigma) (27) (29) , was obtained from Genzyme (Boston). This material was provided in sterile 0.15 M NaCl with 5% fetal calf serum and was reported to contain thymocyte costimulation activity (32) at 100 U/ml, <1.0% T-cell growth factor, interferon at <1 U/ml, and undetectable endotoxin activity. Two distinct species of human rIL-1, expressed from different complementary DNAs (cDNAs) in E. coli and termed rIL-la and rIL-1,3 (30) , were purified (108 U/mg of protein in thymocyte costimulation assays) and supplied as 1000 U/ml in sterile phosphate-buffered saline containing 0.1% bovine serum albumin (Genzyme). Each of the IL-1 preparations was active, and rTNF was inactive, in a comitogenesis assay using the D10.G4.1 T cell line (31) (courtesy of A. Abbas, Brigham and Women's Hospital, Boston). A rabbit antiserum was prepared to purified rTNF (anti-rTNF), and the immunoglobulin fraction of a rabbit antiserum to hmIL-1 (antihmIL-1) was purchased from Genzyme. These antisera neutralized the appropriate monokine in standard bioassays (TNF, L929 cytotoxicity; IL-1, thymocyte costimulation).
Cell Treatments. Cell monolayers were washed three times, incubated for up to 60 min at 37°C, and washed again prior to treatment with TNF or IL-1 in 0.5 ml of pretreatment media. Several pretreatment media, including RPMI 1640 (M. A. Bioproducts) with 10% fetal calf serum (RPMI/10% FCS) or 0.1% bovine serum albumin (RPMI/0.1% BSA), were tested and produced comparable results. After incubation (37°C, 5% C02) for up to 28 hr, each well was washed three times in 0.5 ml of RPMI 1640 medium and prepared for evaluation of PCA.
In certain experiments, cycloheximide (10 ug/ml) or actinomycin D (5 ,g/ml) (Sigma) was added to the cultures 30 min prior to the addition of cytokines and allowed to remain throughout the pretreatment phase. In pilot experiments, this concentration of cycloheximide blocked greater than 97% of [35S]methionine incorporation into endothelial monolayers.
Evaluation of Endothelial PCA. To determine total cellular PCA, a standard one-stage clotting (plasma recalcification) assay was performed as described (21) at 37°C, using glass tubes containing 100 ,ul of citrate-treated, pooled, normal donor, platelet-poor plasma, or coagulation factor VII-, IX-, or X-deficient plasma (George King Bio-Medical, Overland Park, KS) to which 100 ,l of cell lysate (frozen-thawed three times, scrape harvested) and 100 ,ul of CaC12 (30 mM) were added. In certain experiments, cell surface-expressed PCA was assayed directly in the culture wells on intact viable monolayers, using a modified clotting assay (21) . Milliunits (mU) of PCA were defined by standard curves developed with rabbit brain thromboplastin (Sigma) and normal, platelet-poor, citrate-treated human plasma; 103 mU of PCA corresponded to a clotting time of 20 sec in the standard assay.
RESULTS rTNF Induces Procoagulant Activity in Cultured Human
Vascular Endothelium. Human endothelial cells, which were isolated from neonatal umbilical cord veins, adult saphenous veins, adult iliac arteries, or adult thoracic aortae and Maintained under standard culture conditions, contained low levels of PCA (Table 1) . After a 4-hr incubation with human rTNF at 100 U/ml each of these endothelial cell types exhibited a dramatic increase in total cellular PCA (4-to 15-fold, 21 experiments) ( Table 1 ). In contrast, a strain of simian virus 40-transformed umbilical vein endothelial cells (28) , which constitutively expresses high levels of PCA (greater than 500 U/105 cells), was not significantly influenced by treatment with rTNF (5 ± 5% above control, mean ± SD, 3 experiments).
The effect of rTNF on endothelial PCA was found to be concentration dependent, time dependent, and reversible. Incubation of human endothelial monolayers for 4 hr with rTNF concentrations as little as 0.8 U/ml consistently increased PCA over basal levels (1.8-to 4.5-fold, P < 0.005, 6 experiments), and rTNF at 500 U/ml resulted in near maximal stimulation (8.1-to 18.8-fold, 6 experiments) (Fig.  1 ). As seen in Fig. 2 , the kinetics of the endothelial-PCA responses to TNF and IL-i were similar. Continuous exposure of HUVEC to either rTNF (500 U/ml) or hmIL-1 (5 U/ml) led to an increase in total cellular PCA, which was first detected at 30-60 min, peaked at -4 hr, and declined toward basal level by 24 hr. Brief exposure (15 min) of the cultures to either rTNF at 100 U/mi or hmIL-l at 5 U/mi, followed by washing, resulted in substantial increases in PCA by 6 hr (not shown). PCA in endothelial cultures that had been treated with rTNF at 100 U/ml for 4 hr, washed, and incubated in the absence of rTNF for an additional 22-24 hr returned to near basal levels. Rechallenge of these cultures with fresh rTNF (100 U/ml) or hmIL-1 (5 U/mi) resulted in a second rise in PCA, which was equivalent (100±+ 14% and 111 ± 10%o, mean ± SD, 3 experiments) to that obtained by primary stimulation of nonpretreated monolayers. Induction of endothelial PCA by rTNF or hmIL-1 was blocked by cycloheximide at 10 ,ug/mi (81 ± 9% and 85 ± 13% inhibition, mean ± SD, 5 experiments) or actinomycin D at 5 ,ug/mi (107 ± 13 and 102 ± 2% inhibition, 5 experiments), indicating the need for de novo protein and RNA synthesis.
Two Distinct Species of rIL-l Induce Endothelial PCA. Recently, it has been established that hmIL-1 consists of several biochemically distinct species (29, 32) , which appear to be encoded by at least two different genes (30, 33) . We recently reported that a lysate of L cells that expressed the cDNA of a species of human IL-1 cloned by Auron et al. (33) (a gift of T. Livelli, Cistron, Pine Brook, NJ) also induced PCA in cultured endothelium (23) . In addition, purified rIL-1 (a gift of C. Dinarello, Tufts University Medical Center, Boston) produced by expression of this same cDNA in E. ccli was also active in our assay (unpublished observations). In the current studies, we have examined the effects of two E. coli-derived purified rIL-1 polypeptides termed rIL-la and rIL-ip (30) . rIL-la is homologous to a previously described murine IL-1 species (34) and is structurally distinct from rIL-l. The cDNA sequence of rIL-ess (30) is identical to that previously reported by Auron et al. (33) and appears to correspond to the predominant species (pI = 7) produced by stimulated human monocytes (29, 30) . As seen in Table 2 , both rIL-la and rIL-1fU induced endothelial PCA. The effects of these distinct species of rIL-l were also found to be concentration dependent, time dependent, and reversible Rabbit antiserum to rTNF (anti-rTNF) or the immunoglobulin fraction of a rabbit antiserum to hmIL-1 (anti-hmIL-1) was incubated (1:600 and 1:15 final dilution, respectively) with control media (RPMI/1Oo FCS) or the indicated mediator (rTNF, 100 U/ml; hmIL-1, 2.5 U/ml; rIL-1a and rIL-1,3, activities equal to 2.5 U/ml of hmIL-1 in D1O.G4.1 comitogenesis assay) in RPMI/10% FCS for 2 hr at 370C and transferred to replicate HUVEC cultures (passage 3).
After 4 hr of incubation, the cultures were assessed for total cellular PCA. Normal rabbit serum and the immunoglobulin fraction of normal rabbit serum did not significantly inhibit monokine induction of PCA (not shown). Data represent mean ± SD from triplicate wells. Similar results were found in three additional experiments.
(not shown). TNF and IL-1 preparations could be inactivated by heat (100°C, 15 min; 92-102% inhibitiop, 4 experiments) and were unaffected by the presence of polymyxin B (50 Ag/ml; 0-11% inhibition, 3 experiments). These observations distinguish the action of the monokines from that of endotoxin, which also can induce endothelial PCA (23, (35) (36) (37) .
A rabbit antiserum prepared to rTNF abolished the PCAinducing activity of rTNF but did not inhibit the actions of hmIL-1, rIL-la, or rIL-lB (Table 2) . Conversely, a second antiserum prepared to hmIL-1 blocked the induction of PCA by all the preparations of IL-1 tested without significantly inhibiting rTNF activity. These observations help to establish that (0) the PCA-inducing activity of each preparation is attributable to a specific monokine rather than some other component, and (it) TNF is not a significant contaminant of the purified natural hmIL-1 preparations used in our studies.
Effects of Combined and Sequential Treatments with rTNF and IL-1 on Endothelial PCA. The effects of combined TNF and IL-1 treatments of endothelial monolayers were found to be additive even at apparent maximal concentrations of the individual monokines. As seen in Fig. 3 , incubation of HUVEC with increasing concentrations of rTNF in the presence of hmIL-1 at 5 U/ml resulted in a greater increase in PCA than did incubation with rTNF alone.
We previously demonstrated (21) that continuous incubation of endothelial monolayers in hmIL-1 at 5 U/ml for 24 hr led to a state of hyporesponsiveness to rechallenge (4 hr) with fresh hmIL-1. In the current experiments, after incubation for 24 hr in rTNF (100 U/ml), the addition of fresh rTNF (100 U/ml) resulted in only a 60 ± 20% increase in PCA (mean ± SEM, 4 experiments). However, the addition of hmIL-1 at 5 U/ml to replicate monolayers that had been treated for 24 hr with rTNF (100 U/ml) resulted in a 420 ± 70% stimulation (4 experiments) . Similarly, endothelial cultures that were pretreated with IL-1 for 24 hr and then rechallenged with TNF demonstrated a significantly greater response than those cultures that were rechallenged with IL-1 (not shown).
Characterization of TNF-and IL-i-Induced Total Celular and Cell Surface PCA. The nature of the PCA inducecr in endothelial cells by rTNF and IL-1 was investigated by using human plasmas deficient in specific coagulation factors. In our standard one-stage clotting assay, total cellular endothelial PCA that had been induced by rTNF or hmIL-1, alone or in combination, was expressed in normal human plasma and factor IX-deficient plasma but not in plasmas that were (Table 3 ). In a modified clotting assay, unstimulated intact monolayers of HUVEC displayed essentially no surface-available PCA (clotting times -500 sec). However, incubation of these cells for 4 hr in rTNF (200-500 U/ml) alone or in combination with hmIL-1 at 5 U/ml resulted in a marked increase in surface PCA (clotting times 110-140 and 55-85 sec, respectively, 2 experiments). Cell surface PCA that had been induced by rTNF, hmIL-1, or both was not expressed in coagulation factor-VII or factor X-deficient plasma but was expressed in factor IX-deficient plasma (not shown). Incubation of endothelial monolayers with rTNF (0.8-500 U/ml) or hmIL-1 (0.5-10 U/ml) for up to 24 hr did not result in apparent cell damage as assessed by trypan blue exclusion (97-101% of controls, 3 (41) .
In the current study, the endothelial PCA induced by TNF and IL-1, alone or in combination, primarily involved a tissue factor-like activity. However, it appears that these monokines can also influence other components of the "endothelial hemostatic/thrombotic balance" (38) . For example, recent experiments indicate that IL-1 treatment of vascular endothelium also results in a decrease in its fibrinolytic activity (42) , thus, potentially favoring the maintenance of fibrin at sites of inflammation. TNF and IL-1 also share at least two other endothelial-directed actions. First, like IL-1 (23, 24) , TNF can increase the adhesiveness of endothelial cell surfaces for leukocytes (43, 44) . Second, both monokines stimulate the expression of the same endothelial activation antigen (25) , which can be found at sites of inflammation in vivo (45) . However, not all endothelial responses to these monokines are identical. For example, long-term incubation (3-4 days) of endothelial cultures with TNF results in increased expression of class I major histocompatibility antigens (46) , whereas IL-1 has no significant effect (unpublished observation).
Actions of TNF and IL-1 on vascular endothelium in vivo may contribute to the development of thrombotic and inflammatory reactions. In particular, we suggest that the effects of these monokines on endothelial PCA may be involved in the development of endotoxin-induced disseminated intravascular coagulation and hemorrhagic necrosis of tumors. To further understand the pathophysiology of TNF-and IL-1-mediated responses in vivo, it will be useful to examine human tissues for the expression of endothelial activation antigens (25) . In addition, it may be important to investigate the actions of these monokines on various types of normal as 1-V ) ii Proc. Natl. Acad. Sci. USA 83 (1986) well as tumor-associated endothelium. Better understanding of the endothelial-directed actions of TNF and IL-1 may contribute to more effective therapeutic interventions in inflammatory and neoplastic diseases.
Note Added in Proof. Since submission of this article, Nawroth and Stern have reported (47) that rTNF treatment of cultured endothelial cells alters their hemostatic properties, in part, through the induction of tissue factor procoagulant activity.
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